• 1
    Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 17411751.
  • 2
    Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611620.
  • 3
    Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218227.
  • 4
    Cvetkovic RS, Wellington K. Valganciclovir: A review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 2005; 65: 859878.
  • 5
    Green M, Avery RK, Preiksaitis J. Cytomegalovirus. Am J Transplant 2004 (Suppl 10); 4: 5158.
  • 6
    Pescovitz M. Valganciclovir: What is the status in solid organ transplantation? Future Virology 2006; 1: 147156.
  • 7
    Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 1999; 39: 800804.
  • 8
    Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 28112815.
  • 9
    Wiltshire H, Hirankarn S, Farrell C et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005; 44: 495507.
  • 10
    Lalezari J, Lindley J, Walmsley S et al. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr 2002; 30: 392400.
  • 11
    Martin DF, Sierra-Madero J, Walmsley S et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346: 11191126.
  • 12
    Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262274.
  • 13
    Caliendo AM, St George K, Kao SY et al. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: Clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients. J Clin Microbiol 2000; 38: 21222127.
  • 14
    Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186: 829833.
  • 15
    Rollag H, Sagedal S, Kristiansen KI et al. Cytomegalovirus DNA concentration in plasma predicts development of cytomegalovirus disease in kidney transplant recipients. Clin Microbiol Infect 2002; 8: 431434.
  • 16
    Sagedal S, Nordal KP, Hartmann A et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000; 70: 11661174.
  • 17
    Razonable RR, Van Cruijsen H, Brown RA et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 2003; 187: 18011808.
  • 18
    Mattes FM, Hainsworth EG, Hassan-Walker AF et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005; 191: 8992.
  • 19
    Gerna G, Lilleri D, Fornara C et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006; 6: 23562364.
  • 20
    Van Der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2006; 37: 693698.
  • 21
    Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. 27–29 February 2004. Herpes 2004; 11: 7786.
  • 22
    Humar A, Uknis M, Carlone-Jambor C, Gruessner RW, Dunn DL, Matas A. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. Transplantation 1999; 67: 9497.
  • 23
    Van Den Berg AP, Van Son WJ, Haagsma EB et al. Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid-organ transplant recipients. Transplantation 1993; 55: 847851.
  • 24
    Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181: 717720.
  • 25
    Humar A, Kumar D, Gilbert C, Boivin G. Cytomegalovirus (CMV) glycoprotein B genotypes and response to antiviral therapy, in solid-organ-transplant recipients with CMV disease. J Infect Dis 2003; 188: 581584.
  • 26
    Scalzo AA, Corbett AJ, Rawlinson WD, Scott GM, Degli-Esposti MA. The inter-play between host and viral factors in shaping the outcome of cytomegalovirus infection. Immunol Cell Biol 2007; 85: 4654.